Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + lapatinib + paclitaxel
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination chemotherapy regimen consisting of gemcitabine (a nucleoside metabolic inhibitor), lapatinib (a dual tyrosine kinase inhibitor targeting EGFR and HER2), and paclitaxel (a taxane). This triplet therapy has been studied primarily for the treatment of HER2-positive breast cancer, showing promising efficacy in phase I clinical trials with manageable toxicity profile.
02
Targets
DNAABCB1 (P-glycoprotein)TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on gemcitabine + lapatinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + lapatinib + paclitaxel.